Marker Therapeutics Inc (MRKR)

[hanscott]

Cool, thanks PL!

I trust our science team so I am confident they know best and the following is mostly just to share anxiety with the board.

For pancreatic, I feel more and more they should take the time to do a P1 with an optimized TAA-peptide mix, and then do a P2.

------------------

I also think/wonder if they are considering switching the chemo adjuvent from FOLFIRINOX to FOLFIRI for maintanance.

FOLFIRI = FOLFIRINOX minus the oxaliplatin, (to reduce peripheral neurotoxicity).


"Since 2011, the FOLFIRINOX regimen is recommended and widely used as first-line treatment for patients with inoperable PDA . . . with a median progression-free survival (PFS) of 6.4 months . . ."

(Their's is a similar patient population: patients with histologically confirmed, nonresectable PDA, but as young as 37yo (range 37 to 74 years, median 60.5 years).)


Adjuvent Folfuri: Folfirinox first-line to Modified Folfirinox for Adjuvent maintanance:
The median PFS under FOLFIRINOX and subsequent FOLFIRI maintenance was 11 months. Overall, 4 (18%) patients developed adverse events higher than grade 2 on FOLFIRI.


Side Effects:
Overall, 4 (18%) patients developed adverse events higher than grade 2 on FOLFIRI. Hematologic side effects were the most common with both neutropenia and anemia in 14% of the patients. In 6 patients, a protocol modification with dose reduction to 75% or interval prolongation to 21 days was necessary.